RQ Bio
7 known investors
Find your way into RQ Bio
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease. It focuses on immunocompromised populations such as newborns, the elderly, and patients with weakened immunity who may not respond well to seasonal vaccines.
Investors · 7
Frazier Life SciencesPalo Alto
LifeArc VenturesLondon
EQT Life Sciencesreported · 2 sourcesLuxembourg · $11M – $66M
Forbionreported · 2 sourcesNaarden
Oxford Science EnterprisesreportedOxford · $63.5K – $31.8M
Wellington ManagementreportedBoston · $5M – $50M
Also in the syndicate · 1
Monograph
Funding
SEC filings, press & company announcements$115M disclosed across 1 round · 2026
- $115MSeries AJun 2026 · 5 sources
Frazier Life Sciences (lead), EQT Life Sciences, Forbion, LifeArc Ventures, Monograph, Oxford Science Enterprises, Wellington Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does RQ Bio do?
- RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease. It focuses on immunocompromised populations such as newborns, the elderly, and patients with weakened immunity who may not respond well to seasonal vaccines.
- Who are RQ Bio's investors?
- RQ Bio's investors include Frazier Life Sciences, LifeArc Ventures, EQT Life Sciences, Forbion, Oxford Science Enterprises, Wellington Management.
- How much funding has RQ Bio raised?
- RQ Bio has disclosed $115M raised across 1 round.